555 related articles for article (PubMed ID: 19168205)
1. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
2. Voided urinary cytology in bladder cancer: is it time to review the indications?
Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N
Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
[TBL] [Abstract][Full Text] [Related]
3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
4. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
5. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
[TBL] [Abstract][Full Text] [Related]
6. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
7. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
9. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
11. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
12. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
13. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
14. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
[TBL] [Abstract][Full Text] [Related]
15. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
16. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
17. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
18. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
20. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
Karakiewicz PI; Benayoun S; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Marberger MJ; Shariat SF
BJU Int; 2006 May; 97(5):997-1001. PubMed ID: 16542342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]